XML 46 R26.htm IDEA: XBRL DOCUMENT v3.24.1

Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses - EUR (€)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	€ 41,024,131	€ 37,526,090	€ 35,697,935
Third-party services [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	31,802,983	28,543,503	28,247,081
Clinical material and related manufacturing services [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	18,109,345	16,194,152	6,615,840
Clinical, pre-clinical studies [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	13,693,638	12,349,351	21,631,240
Employee benefits expenses [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	6,776,853	6,957,866	5,941,813
Equity-settled share-based payment expense [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	1,500,670	2,456,571	1,622,898
Legal and consulting fees [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	1,758,283	1,690,448	1,074,710
Other expenses [Member]
Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]
Research and development expenses	€ 686,012	€ 334,273	€ 434,331

X

- Definition

The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2023-01-01
-Paragraph 126
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems
Namespace Prefix:	ifrx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_ManufacturingOfClinicalMaterialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_clinicalPreclinicalStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: